Invest in Arcus Biosciences for a strong buying opportunity with promising data, robust pipeline, and significant market ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) today. The company’s ...

Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...

In a report released today, Jason Zemansky from Bank of America Securities maintained a Hold rating on Arcus Biosciences (RCUS – Research ...

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

BMO Capital Markets upgraded shares of Precision BioSciences (NASDAQ:DTIL – Free Report) from a market perform rating to an outperform rating in a report released on Friday, Marketbeat Ratings reports ...

Etrumadenant is under clinical development by Arcus Biosciences and currently in Phase II for Metastatic Colorectal Cancer.

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biotechnology company focused on developing innovative cancer therapies, has been garnering attention from investors and analysts alike due to its ...

HAYWARD, Calif., December 19, 2024--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and ...

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biotechnology company focused on developing innovative cancer therapies, has been garnering attention from investors and analysts alike due to its ...

Long term Arcus Biosciences, Inc. (NYSE:RCUS) shareholders know that all too well, since the share price is down considerably over three years. Unfortunately, they have held through a 65% decline ...

Arcus Biosciences Stock Performance NYSE:RCUS opened at $15.46 on Friday. The company’s 50-day moving average is $16.41 and its two-hundred day moving average is $16.06. Arcus Biosciences, Inc ...